Praetego, derived from the Latin word meaning to protect, is a renowned pharmaceutical company dedicated to safeguarding patients from neurodegenerative diseases associated with aging, with a primary focus on Alzheimer's disease. Grounded in rigorous scientific research, Praetego utilizes its pioneering small molecule series, the Amadorins, to offer systemic protection against chronic diseases linked with aging. The core mission of Praetego is to provide a potent oral drug for neurodegenerative diseases.

Their proprietary small molecule technology effectively targets and inhibits a key driver of disease pathology in neurodegeneration, diabetic microvascular disease, and aging. The company's management team, led by accomplished clinicians and industry experts, spearheads the discovery and development of the Amadorins. Backed by extensive technical and operational expertise, Praetego is well-equipped to navigate the complexities of developmental stage drug companies.

Praetego's pipeline showcases the promising potential of their Amadorins. With preclinical proof of efficacy in Alzheimer's disease and Diabetic Peripheral Neuropathy, their lead candidates, PTG-630 and PTG-670, stand at the forefront of their development efforts. Alzheimer's disease remains the focal point of the pipeline, complemented by Praetego's initiatives in Diabetic Peripheral Neuropathy and Diabetic Retinopathy.

Recognized for their groundbreaking research, Praetego has received prestigious awards and grants. The National Eye Institute recently granted them a $0. 3M STTR award to advance their novel oral drug for Diabetic Retinopathy.

Additionally, the National Institute of Aging awarded Praetego a substantial $2. 5M STTR award to further their work in combating Alzheimer's disease. Located in Durham, NC, Praetego is committed to driving innovation and providing vital protection for patients facing neurodegenerative diseases.

For more information, visit their website at praetego. com